Key Takeaways
- • U.S. life sciences real estate inventory spans over 400 million square feet across more than 3,100 buildings, with Tier 1 clusters in Boston/Cambridge, South San Francisco, and San Diego commanding the largest established inventories and attracting top talent.
- • Boston, San Francisco Bay Area, and San Diego remain the dominant life sciences hubs, supported by strong academic institutions and entrenched industrial clusters, though emerging markets like Raleigh-Durham and Washington D.C. Metro are showing resilience and outperformance in select metrics.
- • Federal funding uncertainty poses material headwinds to long-term sector growth, with proposed NIH budget cuts threatening the early-stage research pipeline that generates biotech startups, while FDA staffing reductions create concerns about drug approval timing and efficiency.
- • Near-term leasing demand faces headwinds despite venture capital recovery, as universities and hospitals—major research property occupants—continue to operate from owned facilities rather than leased space, limiting immediate demand drivers.
- • Pharmaceutical tariff exposure and pricing pressure from "most favored nation" policies compound investor risk perception, threatening industry profitability alongside broader macroeconomic uncertainties affecting capital deployment in the sector.
Summary
The U.S. life sciences real estate market encompasses over 400 million square feet distributed across more than 3,100 buildings, according to industry tracking data from PwC and Revista. This substantial asset base reflects the sector's critical importance to pharmaceutical research, development, and manufacturing operations. The geographic concentration of life sciences real estate remains highly pronounced, with three Tier 1 clusters—Boston/Cambridge, South San Francisco, and San Diego—anchoring the market as the most established clusters with the largest inventories. These markets continue to benefit from proximity to world-class research institutions, established biotech ecosystems, and superior talent pools. Supporting tier-two markets include Raleigh-Durham, Washington D.C. Metro (including Maryland and Virginia), Seattle, New York City, and Philadelphia, with California, Massachusetts, New York, Texas, Pennsylvania, and Florida identified as the top states for biotech, pharma, and life sciences clusters.
The postpandemic real estate landscape has created structural challenges despite apparent sector recovery. While venture capital funding has increased entering 2025, and new project completions peaked in 2024 with construction starts subsequently declining, the actual leasing recovery remains uneven across markets. A significant constraint stems from the occupancy patterns of major space users: universities and hospitals—which conduct foundational research generating the startup pipeline—continue to operate predominantly from owned properties rather than leased facilities. This ownership structure limits near-term leasing demand growth despite improvements in capital availability.
Federal policy headwinds present material long-term risks to sector fundamentals. Proposed National Institutes of Health budget cuts directly threaten early-stage research funding, which flows primarily to universities and hospitals. Since most biotech startups originate from this foundational research environment, reductions in NIH funding could substantially constrain the pipeline of new companies emerging in coming years. This concern extends beyond immediate budget cycles and reflects structural challenges to innovation capacity. Additionally, Food and Drug Administration staffing reductions raise concerns about drug approval timing and process efficiency, creating operational uncertainty for companies navigating regulatory pathways.
Beyond federal policy, industry-specific pressures are compounding investor risk assessments. Proposed pharmaceutical tariffs threaten to increase costs materially for companies reliant on global suppliers, while concurrent policy efforts to enforce "most favored nation" pricing standards are pressuring industry profitability across the sector. These cost and revenue pressures, combined with broader policy uncertainty, are elevating risk perceptions among institutional investors considering capital allocation to life sciences real estate and related ventures. While the sector demonstrated resilience through the pandemic period, the current policy environment suggests a more cautious investment posture may be warranted in the near to medium term.
The postpandemic real estate landscape has created structural challenges despite apparent sector recovery. While venture capital funding has increased entering 2025, and new project completions peaked in 2024 with construction starts subsequently declining, the actual leasing recovery remains uneven across markets. A significant constraint stems from the occupancy patterns of major space users: universities and hospitals—which conduct foundational research generating the startup pipeline—continue to operate predominantly from owned properties rather than leased facilities. This ownership structure limits near-term leasing demand growth despite improvements in capital availability.
Federal policy headwinds present material long-term risks to sector fundamentals. Proposed National Institutes of Health budget cuts directly threaten early-stage research funding, which flows primarily to universities and hospitals. Since most biotech startups originate from this foundational research environment, reductions in NIH funding could substantially constrain the pipeline of new companies emerging in coming years. This concern extends beyond immediate budget cycles and reflects structural challenges to innovation capacity. Additionally, Food and Drug Administration staffing reductions raise concerns about drug approval timing and process efficiency, creating operational uncertainty for companies navigating regulatory pathways.
Beyond federal policy, industry-specific pressures are compounding investor risk assessments. Proposed pharmaceutical tariffs threaten to increase costs materially for companies reliant on global suppliers, while concurrent policy efforts to enforce "most favored nation" pricing standards are pressuring industry profitability across the sector. These cost and revenue pressures, combined with broader policy uncertainty, are elevating risk perceptions among institutional investors considering capital allocation to life sciences real estate and related ventures. While the sector demonstrated resilience through the pandemic period, the current policy environment suggests a more cautious investment posture may be warranted in the near to medium term.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.